Publication: Hemostatic and thrombotic markers in patients with hemoglobin E/β-thalassemia disease
dc.contributor.author | Pantep Angchaisuksiri | en_US |
dc.contributor.author | Vichai Atichartakarn | en_US |
dc.contributor.author | Katcharin Aryurachai | en_US |
dc.contributor.author | Napaporn Archararit | en_US |
dc.contributor.author | Suporn Chuncharunee | en_US |
dc.contributor.author | Arjit Tiraganjana | en_US |
dc.contributor.author | Sasivimol Rattanasiri | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.contributor.other | Faculty of Medicine, Ramathibodi Hospital, Mahidol University | en_US |
dc.date.accessioned | 2018-08-24T01:58:56Z | |
dc.date.available | 2018-08-24T01:58:56Z | |
dc.date.issued | 2007-11-01 | en_US |
dc.description.abstract | Increased frequency of thrombosis has been observed in patients with hemoglobin E/β-thalassemia (Hb E/β-thal) disease, particularly those who have previously been splenectomized. We compared various hemostatic and thrombotic markers in blood from 15 Hb E/β-thal patients who were not splenectomized (NS), 15 who had been splenectomized (S), and 15 normal controls (NC). Levels of plasma thrombin-antithrombin, β2 thromboglobulin, C-reactive protein, tissue plasminogen activator antigen were significantly higher in the S group than in either the NS or the NC groups, and levels of prothrombin fragment 1.2 were significantly higher in the S than in the NC group. Levels of plasminogen activator inhibitor-1 antigen were significantly higher in the S than in the NS group. Levels of protein C, protein S, antithrombin, and fibrinogen were significantly lower in the S and NS groups than in the NC group. Plasma lipoprotein(a) levels in the S and NS groups were not statistically different from NC. Our findings indicated that there is evidence of chronic low-grade coagulation and platelet activation, chronic low-grade inflammation, endothelial cell injury, impaired fibrinolysis, and decreased naturally occurring anticoagulants in splenectomized Hb E/β-thal patients. These changes may account for the increased risk of thrombosis in these patients. © 2007 Wiley-Liss, Inc. | en_US |
dc.identifier.citation | American Journal of Hematology. Vol.82, No.11 (2007), 1001-1004 | en_US |
dc.identifier.doi | 10.1002/ajh.20945 | en_US |
dc.identifier.issn | 10968652 | en_US |
dc.identifier.issn | 03618609 | en_US |
dc.identifier.other | 2-s2.0-35548988928 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/24689 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=35548988928&origin=inward | en_US |
dc.subject | Medicine | en_US |
dc.title | Hemostatic and thrombotic markers in patients with hemoglobin E/β-thalassemia disease | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=35548988928&origin=inward | en_US |